000285810 001__ 285810
000285810 005__ 20260401141742.0
000285810 0247_ $$2doi$$a10.1016/j.jddst.2025.107497
000285810 0247_ $$2ISSN$$a1157-1489
000285810 0247_ $$2ISSN$$a1773-2247
000285810 037__ $$aDZNE-2026-00346
000285810 082__ $$a610
000285810 1001_ $$00009-0008-9173-6975$$aShahid, Hadiqa$$b0
000285810 245__ $$aA Systematic Review of the Applications of Carbon Dots for the Treatment of Diabetes
000285810 260__ $$aParis$$bEd. de Santé$$c2025
000285810 3367_ $$2DRIVER$$aarticle
000285810 3367_ $$2DataCite$$aOutput Types/Journal article
000285810 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1775045750_19741$$xReview Article
000285810 3367_ $$2BibTeX$$aARTICLE
000285810 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285810 3367_ $$00$$2EndNote$$aJournal Article
000285810 520__ $$aDiabetes mellitus is a chronic disease which is defined by persistent hyperglycemia and long-term complications which include neuropathy, nephropathy, and impaired wound healing. Conventional therapies face limitations like side effects, poor drug bioavailability, and invasive monitoring methods. This systematic review examines the recent studies that have been done for the use and administration of carbon dots (CDs), that are small biocompatible nanomaterials for diabetes treatment and diagnosis. Drawing from in vitro and in vivo studies, we highlight the nitrogen-doped CDs for α-glucosidase inhibition, plant-derived CDs for glucose regulation, sulfur and boron/sulfur-doped CDs for non-enzymatic glucose sensing, nitrogen-doped and metformin-derived CDs for insulin delivery, chiral CDs for amyloid aggregation control, Arg CDs and pristine C60 fullerenes for antioxidant and anti-inflammatory activity, Zingiberis-based CDs for hepatoprotection, Zn/C-dots and VEGF-loaded nanodots for wound repair and nerve regeneration and glucose-derived CDs for blood-brain barrier penetration. These functionalized systems use heteroatom doping and surface engineering to combine therapeutic and diagnostic potential, protect β-cells, improve medication absorption, and allow non-invasive glucose monitoring. Notably, several nanodots originally developed for unrelated biomedical purposes have also shown properties beneficial for diabetes management, showing opportunities for repurposing, though further validation in diabetic models is required. While CDs show promise as an integrated platform for managing diabetes and its complications, critical challenges remain in achieving scalable, reproducible synthesis, ensuring long-term safety, and optimizing targeted biodistribution. Future work should prioritize standardized production, mechanistic studies and extended preclinical and clinical evaluation to facilitate translation into effective, patient-friendly nanotherapeutics.
000285810 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285810 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000285810 7001_ $$00000-0002-2996-9152$$aSohail, Tehreem$$b1
000285810 7001_ $$0P:(DE-2719)9001208$$aNoor, Aneeqa$$b2
000285810 7001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b3$$eLast author$$udzne
000285810 773__ $$0PERI:(DE-600)2141013-6$$a10.1016/j.jddst.2025.107497$$gVol. 114, p. 107497 -$$p107497$$tJournal of drug delivery science and technology$$v114$$x1157-1489$$y2025
000285810 8564_ $$uhttps://pub.dzne.de/record/285810/files/DZNE-2026-00346_Restricted.pdf
000285810 8564_ $$uhttps://pub.dzne.de/record/285810/files/DZNE-2026-00346_Restricted.pdf?subformat=pdfa$$xpdfa
000285810 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285810 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285810 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ DRUG DELIV SCI TEC : 2015
000285810 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000285810 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000285810 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000285810 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000285810 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000285810 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000285810 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000285810 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000285810 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000285810 980__ $$ajournal
000285810 980__ $$aEDITORS
000285810 980__ $$aVDBINPRINT
000285810 980__ $$aI:(DE-2719)1440011-1
000285810 980__ $$aUNRESTRICTED